In a recent report of a phase 1 trial testing a CD22targeted CAR-T cell therapy in 21 children and adults, including 17 who were previously treated with CD19-directed immunotherapy, dose-dependent antileukemic activity was observed, with complete remission achieved in 11 of the 15 patients receiving ≥ 1 ± 106 CD22-CART cells per kg of body weight, including all 5 patients with CD19dim or CD19– B-ALL [68]. Here, CD19 is linked to acute lymphoblastic leukemia.